MENU

ImvivaBio CTA313: Dual CD19/BCMA CAR-T Data for Lupus in 2026

Yahoo Finance(GlobeNewswire) USA
Overview
ImvivaBio presented 12-month follow-up data for CTA313, an allogeneic dual-targeted CD19/BCMA CAR-T therapy for systemic lupus erythematosus (SLE) and lupus nephritis (LN). The therapy demonstrated durable remission, with DORIS remission reaching 88% at Month 12 in refractory SLE patients. These results suggest a potential “immune reset” mechanism that provides superior disease control compared to single-target CD19 approaches.
In Depth

Key Findings

CTA313 induced durable remission and immune reconstitution in patients with refractory SLE. In a pooled analysis of 14 heavily pretreated patients with minimal renal involvement, DORIS remission reached 73% at Month 6 and 88% (7/8 patients) at Month 12. Additionally, 92.9% of these patients were off immunosuppressants at the data cutoff, and 92% of evaluable patients were taking glucocorticoids at 5 mg/day or less by Month 6.

Technical Details

CTA313 is an off-the-shelf allogeneic CAR-T therapy targeting both CD19 and BCMA to prevent relapses caused by autoreactive B-cell precursors or plasma-cell reservoirs. Technical data highlights include:

  • B-cell Dynamics: B cells dropped from a median of 52.2 to 0 cells/µL by Day 7, reconstituting around Day 42 with over 95% naive phenotype. Single-cell analysis showed no overlap between pretreatment autoreactive clones and new clones.
  • Biomarkers: Anti-dsDNA antibodies became undetectable by Month 3 and remained so for up to one year. Complement component C3 rose from 0.65 to 1.34 g/L by Day 28.
  • Comparative Efficacy: In SLE with minimal renal involvement, the dual-target approach achieved 80% DORIS remission at Month 12, compared to 20% for single-target CD19 CAR-T.
  • Safety: Cytokine release syndrome (CRS) occurred in 35.7% of patients (all Grade 1). No neurotoxicity or graft-versus-host disease (GvHD) was observed. Grade 3 or higher adverse events included neutropenia (71.4%), thrombocytopenia (21.4%), and infections (21.4%).

Background and Significance

Current standard-of-care for SLE and LN relies on broad immunosuppression, which often results in incomplete responses and toxicity. By targeting both CD19 and BCMA, CTA313 aims to achieve a deeper B-cell eradication and a complete immune reset. These findings support the transition of CTA313 into the upcoming global Phase 1b ALLNEW basket study to evaluate durable disease control in a broader patient population.

Source: https://finance.yahoo.com/healthcare/articles/imvivabio-presents-longer-term-data-130000771.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

  • Your email and selected fields are used only to deliver the newsletter.
  • We never share your information with third parties.
  • You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Takes about a minute · Unsubscribe anytime

Published by Troy-Technical, an independent site run by one engineer with a career in materials development.
About the author / Contact info@troy-technical.jp
Let's share this post !

Author of this article

TOC